Compare UMC & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UMC | UTHR |
|---|---|---|
| Founded | 1980 | 1996 |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.2B | 23.9B |
| IPO Year | 1997 | 1999 |
| Metric | UMC | UTHR |
|---|---|---|
| Price | $9.51 | $540.03 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 14 |
| Target Price | N/A | ★ $531.79 |
| AVG Volume (30 Days) | ★ 6.0M | 469.4K |
| Earning Date | 01-01-0001 | 05-28-2026 |
| Dividend Yield | ★ 3.90% | N/A |
| EPS Growth | N/A | ★ 13.07 |
| EPS | N/A | ★ 27.86 |
| Revenue | N/A | ★ $1,483,300,000.00 |
| Revenue This Year | $11.46 | $7.77 |
| Revenue Next Year | $10.06 | $11.11 |
| P/E Ratio | ★ $18.95 | $19.17 |
| Revenue Growth | N/A | ★ 2.38 |
| 52 Week Low | $5.71 | $266.98 |
| 52 Week High | $12.68 | $548.12 |
| Indicator | UMC | UTHR |
|---|---|---|
| Relative Strength Index (RSI) | 44.47 | 62.53 |
| Support Level | $7.58 | $464.92 |
| Resistance Level | $11.04 | $542.66 |
| Average True Range (ATR) | 0.25 | 16.05 |
| MACD | -0.10 | 3.76 |
| Stochastic Oscillator | 20.50 | 89.20 |
Founded in 1980, United Microelectronics is the world's third-largest dedicated chip foundry, with 5% market share in 2024 after TSMC and SMIC. UMC's headquarters are in Hsinchu, Taiwan, and it operates 12 fabs in Taiwan, Mainland China, Japan and Singapore, with additional sales offices in Europe, the US, and South Korea. UMC features a diverse customer base that includes Texas Instruments, MediaTek, Intel, Broadcom, Novatek, and Realtek, supplying a wide range of products applied in communications, display, memory, automotive and more. UMC employs about 19,000 people as of February 2025.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.